A Phase I Trial To Evaluate Safety And Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant In Recipients Of Allogeneic Hematopoietic Stem Cell Transplant

Trial Profile

A Phase I Trial To Evaluate Safety And Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant In Recipients Of Allogeneic Hematopoietic Stem Cell Transplant

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs CMV-pp65-vaccine-PepVax (Primary) ; PF 3512675
  • Indications Cytomegalovirus infections; Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 May 2017 Planned End Date changed from 1 Aug 2014 to 1 Oct 2017.
    • 23 Nov 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top